The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
Merck and Daiichi Sankyo announced. Oncternal Therapeutics announced termination of a clinical trial of the androgen receptor inhibitor ONCT-534 in metastatic castration resistant prostate cancer and ...
BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...
Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...
This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Artificial heart maker Carmat on Wednesday announced the launch of a new capital increase for an initial amount of 10.3 ...
Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback